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Noncompetitive Antibody Neutralization of IL-10
Revealed by Protein Engineering
and X-Ray Crystallography
2-fold-related domains are comprised of four helices
(A–D) from one chain and two helices (E and F) from the
other chain [4, 5]. Recently, the crystal structure of the
complex between IL-10 and a soluble form of its high
affinity receptor (sIL-10R1) revealed that identical sur-
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of one or two IL-10R1s and IL-10R2s bound to one IL-
10 dimer or may require a larger complex consisting of
two IL-10 dimers, two IL-10R1s, and two IL-10R2s [6].Summary
Previously, to determine whether the assembly and or-
ganization of this complex requires the IL-10 dimer, weIL-10 is a dimeric cytokine that must engage its high-
mutated the IL-10 chain to fold as a single helical domainaffinity cell surface receptor, IL-10R1, to induce multi-
(IL-10M1) that could only bind one IL-10R1 chain [7]. IL-ple cellular activities. Here we report the 1.9 A˚ crystal
10M1 is the “unswapped” monomer of IL-10 and wasstructure of an engineered IL-10 monomer (IL-10M1)
created by inserting six residues (GGGSGG, 116A–116F)in complex with a neutralizing Fab fragment (9D7Fab).
between Asn116 and Lys117 of the IL-10 DE loop. Sur-9D7Fab and IL-10R1 bind distinct nonoverlapping sur-
prisingly, IL-10M1 demonstrated activity in B cell prolif-faces on IL-10M1. Antagonism of the IL-10M1/IL-10R1
eration assays and did not antagonize cellular IL-10,interaction is the result of 9D7Fab-induced conforma-
indicating that IL-10 signaling does not require the IL-tional changes in the CD loop of IL-10M1 that indirectly
10 dimer.alter the structure of the IL-10R1 binding site. A single
Initially, we were interested in determining the crystalmutation (Ile87Ala) in the same CD loop region of the
structure of IL-10M1 to evaluate our protein engineeringEpstein-Barr virus IL-10 (ebvIL-10) also reduces IL-
studies. However, crystallization of IL-10M1 required it10R1 binding affinity, suggesting that ebvIL-10 and
to be complexed with a Fab fragment from a neutralizing,9D7Fab use similar allosteric mechanisms to modulate
rat IgG1, anti-IL-10, monoclonal antibody (9D7Fab) [8].IL-10R1 affinity and biological activity.
Unexpectedly, the structure of the IL-10M1/9D7Fab
complex revealed that IL-10R1 and 9D7Fab bind distinct
Introduction nonoverlapping sites on IL-10M1. We confirmed that
9D7Fab could also neutralize IL-10 and IL-10M1 activity
IL-10 suppresses the production of inflammatory cyto- in B cell proliferation assays, indicating that the mecha-
kines by T cells, macrophages, monocytes, dendritic nism of 9D7 neutralization may be understood by analy-
cells, and neutrophils and downregulates the expression sis of the IL-10M1/9D7Fab complex structure. Structural
of MHC class II and costimulatory molecules by macro- comparisons of 9D7Fab-bound IL-10M1 with free and
phages and monocytes [1]. In contrast to its broad im- receptor-bound IL-10, as well as biochemical analysis,
munosuppressive effects, IL-10 also stimulates B cell, revealed that 9D7Fab antagonizes the interaction be-
mast cell, and thymocyte proliferation. As a protein ther- tween IL-10 and its high affinity receptor, IL-10R1, by
apeutic, IL-10 is potentially useful in the treatment of an allosteric mechanism.
several chronic autoimmune diseases, including inflam-
matory bowel disease and rheumatoid arthritis. Results and Discussion
Responses to IL-10 can also be deleterious, effec-
tively lowering host resistance to microbial pathogens Structure Solution
and enhancing the growth of some B cell tumor cell The IL-10M1/9D7Fab crystals belong to space group
lines in vitro [1]. In animal models, anti-IL-10 monoclonal P21 (a  82.6 A˚, b  75.6 A˚, c  112.0 A˚, and   96.9)antibodies have been shown to increase host resistance and contain two complexes in the asymmetric unit. The
to several pathogenic bacteria, mycobacteria, fungi, and structure was solved to 1.9 A˚ resolution by molecular
protazoa [1]. Additionally, these antibodies lower the B replacement and refined to R 18.7% and Rfree  24.0%cell proliferation and high serum levels of autoantibodies (Table 1). The final model includes the complete Fab
associated with systemic lupus erythematosis and have fragment and residues 21–115 and 117–157 (IL-10 num-
proven effective in a limited human trial [1]. bering) of IL-10M1 for each of the two complexes in the
Cellular responses to IL-10 are the result of an intracel- asymmetric unit. IL-10M1 residues at the N and C termini
lular signaling cascade that is initiated by the sequential (8–20 and 158–160) and the DE loop (116–116F) were
assembly of IL-10 with its high (IL-10R1)- and low (IL- not visible in the electron density and were omitted from
10R2)-affinity cell surface receptors [2, 3]. IL-10 is the final model.
a noncovalent domain-swapped dimer in which the
Key words: crystal structure; cytokine; IL-10; neutralizing antibody;
noncompetitive; protein engineering4 Correspondence: walter@uab.edu
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Table 1. Crystallographic Data and Model Refinement
Data Collection
Space group P21












Number of protein atoms 8,771





Most favored (number of residues) 89.8% (885)
Additionally favored (number of residues) 8.8% (87)
Generously allowed (number of residues) 1.0% (10)
Disallowed (number of residues) 0.4% (4)
a Numbers in parentheses correspond to highest resolution shell (1.95–1.91 A˚).
b Rsym  (|Ihkl  I|)/(Ihkl), where the average intensity I is taken over all symmetry equivalent measurements and Ihkl is the measured
intensity for any given reflection.
The IL-10M1/9D7Fab Complex water molecules, form a continuous network of 45 H
bonds and/or salt bridges (donor/acceptor 3.4 A˚).In the IL-10M1/9D7Fab complex (overall dimensions of
100 A˚	 52 A˚	 36 A˚), the helix bundle of IL-10M1 makes The most extensive interactions are made by IL-10M1
residues Gln132 and Glu133, which account for 30%an angle of 45 with the pseudo-2-fold axis relating
the VH and VL chains of 9D7Fab (Figure 1A). The two of the total buried surface of IL-10M1 (Figure 1B). These
two residues, located in the turn connecting helices Ecomplexes in the asymmetric unit are related by a non-
crystallographic pseudo-2-fold screw axis, and super- and F, are completely buried (237 A˚2 of 245 A˚2 ) in a
cavity formed by the 9D7Fab VL and VH chains. At theposition of all C
 atoms results in a root-mean-square
deviation (rmsd) of 0.55 A˚. The rmsd reflects a slight base of this cavity, the carboxylate oxygens of Glu133
make four hydrogen bonds with the side chains of resi-variation of the Fab elbow angles [9], as the isolated
constant, variable, and IL-10M1 domains can be super- dues in the CDR L1, L3, and H3 loops, Arg3132, Ser9091,
and Asn104100, respectively. Adjacent to the cavity is aimposed with rmsds of 0.35 A˚, 0.36 A˚, and 0.48 A˚, re-
spectively. relatively flat but complementary surface, formed by the
heavy chain CDR loops, that interacts with residues on
one face of helix C and the CD loop. Side chain and main9D7Fab
9D7Fab residues are numbered sequentially and refer- chain atoms from Glu75, Asn82, and Gln83 participate in
seven hydrogen bonds, six with CDRH2 and CDRH3 andenced throughout with Kabat [10] numbering following
in subscript. The 9D7Fab CDR loops L1, L2, L3, H1, and one with CDRL1. Interestingly, the N-terminal residue
of the 9D7Fab light chain, Asp11, also makes a specificH2 are observed in conformations consistent with the
canonical classes predicted by their sequences, 2, 1, 1, interaction with IL-10M1, forming a salt bridge with
Lys130.1, and 2, respectively [11]. As observed in the structures
of other Fab fragments possessing class 2 CDRL1 and
class 1 CDRL2 loops, residues Thr2930 and Ala5051 ex-
hibit phi-psi angles in disallowed regions of a Rama- 9D7 Noncompetitively Antagonizes
IL-10R1 Bindingchandran plot in each of complexes in the asymmetric
unit [12]. 9D7Fab-bound IL-10M1 was superimposed onto the do-
mains of the IL-10 dimer in the IL-10/sIL-10R1 complex
(Protein Data Bank code 1J7V [6]). The resulting IL-10/IL-10M1/9D7Fab Interface
The six 9D7Fab CDR loops interact with a discontinuous IL-10R1/9D7Fab ternary complex model clearly demon-
strates that 9D7Fab and IL-10R1 bind distinct nonover-IL-10M1 epitope comprised of residues 71–83 and 125–
137 (Figure 1B). A total of 16 IL-10M1 and 22 9D7Fab lapping IL-10 surfaces (Figures 2A and 2B). Thus,
9D7Fab does not neutralize IL-10M1 by stericallyresidues bury 808 A˚2 and 753 A˚2 of surface area in the
interface, respectively. Seventy percent (27 of 38) of “blocking” the IL-10R1 binding site. This suggested that
9D7Fab binding induces conformational changes in IL-these residues are polar and, along with eight interfacial
Noncompetitive Antibody Neutralization of IL-10
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Figure 1. The IL-10M1/9D7Fab Complex and
Interface
(A) Ribbon diagram of the IL-10M1/9D7Fab
complex with IL-10M1 in orange and the
9D7Fab heavy and light chains in red and
blue, respectively. The 9D7Fab epitope, resi-
dues 71–83 and 125–137, is in green.
(B) Stereo diagram of the IL-10M1/9D7Fab
interface colored as described in panel A. Ni-
trogen atoms, blue; oxygen atoms, red; in-
terfacial waters, magenta spheres; hydrogen
bonds, dashed black lines.
10M1 that indirectly disrupt the IL-10R1 binding site, 3B). In the IL-10M1/9D7Fab complex, 9D7Fab light chain
residues Arg3132 and Trp9192 cause the phenol group ofresulting in neutralization of IL-10M1 activity.
To test this hypothesis, 9D7Fab-bound IL-10M1 was Tyr137 to rotate by 90 relative to Tyr137 in receptor-
bound IL-10. Furthermore, interactions between CDRH3compared with free (Protein Data Bank code 2ILK [13])
and sIL-10R1-bound (Protein Data Bank code 1J7V [6]) residues Pro10197 and Gly10298 with IL-10M1 residues
Asn82 and Gln83 result in an2 A˚ rigid-body movementIL-10 (Figure 2B). Except for residues 38–44 within the
IL-10R1 binding site, IL-10M1 is structurally equivalent of the entire CD loop. These changes disrupt hydropho-
bic and electrostatic interactions between Lys40 and(rmsd of 0.8 A˚ for 129 C
 pairs) to one domain of
the receptor-bound or free IL-10 dimer. In the IL-10M1/ IL-10 scaffold residues Asp84 and Tyr137, which, in the
IL-10/IL-10R1 complex, appear to stabilize the last turn9D7Fab complex, residues 38–44 are not involved in
extensive crystal-packing interactions and should re- of helix A (Gln38, Met39, and Lys40) and the AB loop
(Asp41, Gln42, Leu43, and Asp44).semble their solution conformations when bound to
9D7Fab. As previously observed for free IL-10 [4, 5], Interestingly, a mutation in this same region has been
found to modulate the affinity of the Epstein-Barr virusresidues 41–45 in the AB loop of IL-10M1 are largely
disordered, as evidenced by their high thermal factors IL-10 homolog (ebvIL-10) for IL-10R1 [14]. ebvIL-10
shares 85% sequence identity with human IL-10 yetand poor electron density (Figure 3A). However, electron
density for residues 38–40 reveals that the C-terminal displays1000-fold-lower affinity for IL-10R1 [15]. Most
of this affinity difference (100-fold) is dependent onend of helix A comprised of Gln38, Met39, and Lys40 is
unwound in the presence of 9D7Fab (Figures 3A and the single mutation of IL-10 residue Ile87 to an alanine
[14]. Ile87 is located in helix D, immediately adjacent to3B). Comparison with sIL-10R1-bound IL-10 shows that
this seemingly subtle conformational change results in the CD loop, and its mutation to alanine may change
the conformation of residues in the IL-10R1 binding sitedifferences in the C
 atom positions of residues 38–44
of up to 8 A˚ (Figure 2B). (Figure 3B). Thus, sequence changes in ebvIL-10 and
9D7Fab-induced conformational changes in IL-10M1 al-Structural changes in residues 38–44 are the result
of 9D7Fab-induced conformational changes in helix F ter the same CD loop region to allosterically modulate
IL-10R1 binding affinity.Tyr137 and CD loop residues Gln83, Asp84, Pro85, and
Asp86. Although these secondary structural elements The ability of these changes to antagonize IL-10R1
binding is consistent with the extensive interaction ofdo not directly contact IL-10R1, they are critical for the
structural integrity of the IL-10R1 binding site (Figure IL-10 residues 38–44 with IL-10R1 [6]. These seven resi-
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isothermal titration calorimetry in the presence and ab-
sence of 9D7Fab (Figure 4B). 9D7Fab bound to IL-10M1
increased the disassociation constant (KD) of IL-10M1
for IL-10R1 from 8 nM to 2 M (250-fold difference).
This indicates that a ternary complex between IL-10M1,
9D7Fab, and sIL-10R1 can be isolated when the concen-
trations of the components are greater than 200 M
(100-fold above Kd for sIL-10R1). As predicted, this ter-
nary complex was isolated by size exclusion chromatog-
raphy of a 250 M IL-10M1, 250 M 9D7Fab, and 250
M sIL-10R1 solution (Figure 5).
Neutralization by 9D7Fab
The250-fold reduction in sIL-10R1 affinity in the pres-
ence of 9D7Fab corresponds to a binding free energy
difference (G) of 3.3 kcal/mol. To put this energy dif-
ference into perspective, single alanine mutations in the
human growth hormone “hotspot” disrupt receptor
binding with G values of 1.1–2.4 kcal/mol [16]. This
suggests that the cumulative energetic effects of the
conformational changes induced by 9D7Fab are equiva-
lent to the mutation of approximately two growth hor-
mone hotspot residues to alanine.
It is unclear whether this energy difference, although
significant, is sufficient to explain the neutralizing effects
of 9D7Fab, which may also involve antagonism of the IL-
10/IL-10R2 interaction. However, given the orientation of
9D7Fab in the IL-10/sIL-10R1/9D7Fab ternary complex
model (Figure 2A), it is unlikely that 9D7Fab sterically
blocks IL-10R2 binding, indicating that antagonism of
IL-10R2 by 9D7Fab is also noncompetitive. Several IL-
10R1 residues that contact IL-10 are conserved in IL-
10R2, suggesting that IL-10R1 and IL-10R2 share a com-Figure 2. Location of 9D7Fab and IL-10R1 Binding Sites and IL-10
mon binding site comprised of helix A, the AB loop,Structural Changes
and helix F [6]. Therefore, in the context of the shared(A) Ribbon diagram of the ternary complex model between IL-10
receptor binding site model, the changes induced by(green), sIL-10R1 (yellow), and 9D7Fab (blue and red). Two 9D7Fab
fragments were positioned by superimposing IL-10M1 from the IL- 9D7Fab within the IL-10R1 binding site would also non-
10M1/9D7Fab complex on each of the domains in the 1:2 IL-10/sIL- competitively antagonize IL-10R2 binding.
10R1 complex (Protein Data Bank code 1J7V). In solution and in the IL-10/sIL-10R1 crystals, IL-10
(B) The upper histogram plot displays the buried surfaces per resi- and sIL-10R1 form a complex of two IL-10 dimers and
due in the interfaces of the IL-10M1/9D7Fab (red) and IL-10/sIL-
four sIL-10R1 chains [6, 17]. The architecture of the 2:410R1 (Protein Data Bank code 1J7V; yellow) complexes. The sec-
complex has been proposed as a model for the activeondary structure is displayed below with 
 helices represented by
IL-10/IL-10R1/IL-10R2 complex, constructed by the re-gray boxes and loops by thin black lines. The lower histogram plot
displays the rmsd between C
 atoms of 9D7Fab-bound IL-10M1 placement of the sIL-10R1 chains bound to one IL-10
and receptor-bound IL-10 (Protein Data Bank code 1J7V; green) or dimer with IL-10R2 [6]. In this model, activation occurs
9D7Fab-bound IL-10M1 and free IL-10 (Protein Data Bank code between IL-10R1 and IL-10R2 bound to adjacent IL-
2ILK; magenta). 10 dimers, rather than across them. Modeling studies
(Figure 6) and size exclusion chromatography (data not
shown) demonstrated that 9D7Fab blocks the assembly
dues participate in 9 of the 20 hydrogen bonds/salt brid- of the 2 IL-10/4 sIL-10R1 complex, indicating that
ges and account for 33% of the IL-10 surface area 9D7Fab may also neutralize IL-10 by preventing the for-
buried in the IL-10/sIL-10R1 interface (Figure 4A). The mation of a similar complex on the cell surface.
conformation of helix A in 9D7Fab-bound IL-10M1 sug- At this time we cannot determine whether 9D7Fab
gests that hydrogen bond interactions between IL-10M1 disrupts IL-10R2 binding and/or the putative 2:2:2 active
Gln38 and IL-10R1 residues Arg76 and Arg96 would be signaling complex. However, each of the mechanisms
completely abolished. It is difficult to determine how the by which 9D7Fab would likely antagonize these interac-
additional receptor contacts will be affected, given the tions are noncompetitive and consistent with the current
flexibility of the AB loop residues 41–44. However, it is model for the biologically active IL-10 signaling com-
unlikely that the “active” conformation of the AB loop plex [6].
observed in the IL-10/sIL-10R1 complex is adopted
when 9D7Fab is bound. Biological Implications
In order to quantitate the effect of 9D7Fab-induced
structural changes on the IL-10M1/IL-10R1 interaction, IL-10 regulates and eventually terminates immune re-
sponses by suppressing the synthesis of proinflamma-we measured the affinity of IL-10M1 for sIL-10R1 by
Noncompetitive Antibody Neutralization of IL-10
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Figure 3. Structural Changes in the IL-10M1
AB Loop
(A) Stereo view of the electron density for the
residues 36–45 in IL-10M1 corresponding to
helix A and the AB loop. The Fo  Fc map is
contoured at 1.7  and was calculated from
six simulated-annealing models from which
residues 35–47 had been removed.
(B) Stereo view ribbon diagram comparing
IL-10M1 (orange) and receptor-bound IL-10
(Protein Data Bank code 1J7V; green). The
9D7Fab heavy and light chains are red and
blue, respectively, with selected side chains
in gray.
tory cell surface proteins, such as MHC class II and which ultimately leads to all of these responses, is initi-
ated by the interaction of IL-10 with IL-10R1. The struc-ICAM-1, and cytokines, including IL-1, IL-6, and TNF, by
many cell types. The IL-10 signal-transduction pathway, ture of the 9D7Fab/IL-10M1 complex revealed that the
Figure 4. Effect of 9D7Fab-Induced Changes on Receptor Binding
(A) Comparison of helix A and AB loop residues for 9D7-bound IL-10M1 (orange) and receptor-bound IL-10 (Protein Data Bank code 1J7V;
green). Helix F, which sits behind the AB loop, has been removed for clarity. Hydrogen bonds between IL-10 and sIL-10R1 (yellow side chains)
in the IL-10/sIL-10R1 receptor complex are indicated. The side chain of IL-10R1 residue R76 has two conformations.
(B) ITC analysis of the interaction between IL-10M1 and sIL-10R1 in the presence of 9D7Fab (orange) compared to the identical experiment
lacking 9D7Fab (green). The top panel contains the raw data for both experiments, and the bottom panel contains a plot of the heat changes
against the ratio of sIL-10R1 to IL-10M1.
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posed as a model for the active cell surface complex,
making 9D7Fab an excellent tool for further studies of
IL-10 signaling.
Experimental Procedures
Protein Expression and Purification
IL-10M1, the IL-10M1 truncation mutant (residues 8–160), and sIL-
10R1 were expressed and purified as previously described [7, 18].
The Fab fragment of 9D7 was cleaved from the intact antibody using
the protease papain and purified by protein A and size exclusion
chromatography. The IL-10M1/9D7Fab complex was formed by mix-
ing the two components, with a slight molar excess of IL-10M1,
purified by size exclusion chromatography and concentrated to ap-
proximately 10 mg ml1 for crystallization.
Crystallization
Initial intergrown rosettes of the IL-10M1/9D7Fab complex were
observed in condition 37 (8% Peg 4000, 0.1 M Na-Acetate [pH 4.6])
of the Crystal Screen I Kit (Hampton) at 4C after several months.
Analysis of these crystals by mass spectrometry revealed that the
first seven residues of IL-10M1 had been protealitically removed.
The recloning of IL-10M1 lacking these residues and the optimiza-
tion of initial conditions to a well solution consisting of 12%–14%
Peg 4000 and 0.1 M Na-Citrate (pH 5.6) resulted in the intergrown
rosettes appearing in 4–7 days. Single diffraction quality crystals
that reached a final size of 0.4 mm 	 0.2 mm 	 0.2 mm were
obtained by streak seeding methods.
Data Collection, Processing, and Molecular Replacement
Data on the complex was collected at the Stanford Synchrotron
Radiation Laboratory (beamline 9-1;   0.98 A˚), equipped with a
MAR 345 image-plate detector, from a single flash-cooled (180C)
crystal. Diffraction data were processed and scaled using MOSFLM
and SCALA [19]. Molecular replacement was performed with
AMORE [20] using one domain of IL-10 (Protein Data Bank code
Figure 5. Isolation of the Ternary IL-10M1/sIL-10R1/9D7Fab
2ILK; residues 19–114 and 118–154) and the structure of a Fab
Complex
fragment from an anti-interferon- monoclonal antibody recently
(A) Analysis of the complexes formed when IL-10M1, sIL-10R1, and solved in our laboratory as the search probe.
9D7Fab are mixed at 250 M by size exclusion chromatography.
(B) Nonreducing SDS-PAGE analysis of the peaks in (A).
Refinement
The molecular replacement solution was rigid-body refined in CNS
[21] (R  48.1% and Rfree  48.1%). A 30-cycle refinement with ARPIL-10/IL-10R1 interaction can be antagonized by an allo- [22] (molrep mode) resulted in a model with R  23.5% and Rfree 
steric mechanism, suggesting new strategies for the 32.5% and an easily interpretable 2Fo  Fc map for most of the
asymmetric unit. Refinement was completed with several cycles ofdesign of IL-10 antagonists. Additionally, this mecha-
manual rebuilding in O [23] followed by simulated annealing andnism explains how a residue, identified by mutational
molecular dynamics in CNS [21]. Model improvement was evaluatedanalysis, that is outside of the IL-10R1 binding site can
by the lowering of R and Rfree, as well as improvement in the electronmodulate the receptor affinity and the biologic profiles
density maps and model geometry, as evaluated by the program
of IL-10 and the Epstein-Barr virus homolog of IL-10. PROCHECK [24]. Coordinate superpositioning was performed by
Lastly, in solution, 9D7Fab blocks the formation of a LSQKAB [19], and figures were generated by the RIBBONS [25]
program suite.large 2 IL-10/4 IL-10R1 complex, which has been pro-
Figure 6. Stereo Model Showing How
9D7Fab Prevents the Formation of the 2 IL-
10/4 sIL-10R1 Complex
The 2 IL-10 dimer/4 sIL-10R1 complex has
been proposed as a model for the active IL-
10/IL-10R1/IL-10R2 complex, constructed by
the replacement of the sIL-10R1 chains
bound to one IL-10 dimer (red) with IL-10R2
(blue) [6]. In this model, activation occurs be-
tween IL-10R1 and IL-10R2 bound to adja-
cent IL-10 dimers, rather than across them.
Steric clashes between the magenta and
cyan 9DFab molecules bound to the green
and the red IL-10 dimers, respectively, would
disrupt the formation of the “active” 2 IL-10
dimer/2 IL-10R1/2 IL-10R2 complex.
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